Nutritional management during chemoradiotherapy for nasopharyngeal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional study at Jiangxi Cancer Hospital gives an immune‑enhancing oral nutritional preparation to adults with histologically confirmed stage II–IVa nasopharyngeal carcinoma who are receiving definitive concurrent chemoradiotherapy. Participants receive nutritional support by mouth or enterally throughout the course of chemoradiotherapy while investigators monitor weight, PG‑SGA scores, lymphocyte counts, and treatment‑related acute toxicities. Eligibility requires adequate performance status, blood counts, and liver and kidney function, and excludes patients with a second primary tumor, uncontrolled metabolic disease, or known allergy to the supplement. The main aim is to see if continuous nutritional management can reduce the severity and delay the onset of acute side effects while preserving nutritional and immune status during therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1.Patients with nasopharyngeal carcinoma confirmed by histopathology;2.Clinical stage stage II-IVa,Concurrent chemoradiotherapy is included in the definitive treatment regimen;3.Age ≥ 18 years, male or female;4.PG-SGA score of 0-8 before radiotherapy;5.KPS score ≥ 60 or ECOG score ≤3;6.Nutritional supplementation can be given by mouth or enterally;7.Patients sign a formal informed consent form to indicate that they understand that this study complies with hospital policies;8.Serum hemoglobin ≥ 90 g/L, platelet ≥ 100×109/L, absolute neutrophil count ≥ 1.5×109/L;9.serum creatinine ≤1.25 times ULN or creatinine clearance ≥60 mL/min;10.Serum bilirubin ≤ 1.5-fold ULN, AST (SGOT) and ALT (SGPT) ≤ 2.5-fold ULN, and alkaline phosphatase ≤ 5-fold ULN.

Exclusion Criteria:

* 1.Have a second primary tumor;2.Those who do not receive concurrent chemoradiotherapy;3.Comorbid diabetes mellitus, or history of severe endocrine and metabolic diseases;4.Those who are allergic to oral nutritional meal replacements.

Where it's running

• Jiangxi Cancer Hospital
  Nanchang, Jiangxi, China Recruiting

Study contacts

• Study coordinator: Yong Su, MD
• Email: 1246256523@qq.com
• Phone: CHINA/360100+13699526170

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured swallowing exercises for nasopharyngeal cancer patients

  This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.

  Recruiting Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT07909538

• Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer

  This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07819656

• Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma

  This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07781358

• Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma

  This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07762976

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma

  This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07618078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.